Form 4: Mineralys Therapeutics Director Alexander M. Gold Acquires 44,000 Stock Options
SEC Form 4 Filing
Director Alexander M. Gold acquired 44,000 stock options in Mineralys Therapeutics, Inc. on June 13, 2024.
Summary
- On June 13, 2024, Alexander M. Gold, a director of Mineralys Therapeutics, Inc., acquired 44,000 stock options.
- The exercise price of these options is $12.69.
- The options vest in 36 monthly installments starting July 13, 2024, and expire on June 13, 2034.
- Following the transaction, Gold directly owns 44,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director. While insider ownership can be a positive signal, this specific event doesn't strongly indicate a bullish or bearish outlook.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedule suggests a long-term commitment from the director.
Industry Context
This is a standard SEC filing related to insider transactions. It's common for directors and officers to receive stock options as part of their compensation, aligning their interests with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of the stock option transaction. |
| 07/13/2024 | First vesting date of the stock options. |
| 06/13/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.